Anika Therapeutics (ANIK) Cash & Current Investments (2010 - 2026)
Anika Therapeutics (ANIK) posted quarterly Cash & Current Investments of $38.4 million for Q2 2026, down 50.19% year-over-year from $77.1 million in Q2 2025, and down 42.49% quarter-over-quarter from $66.8 million in Q1 2026.
Anika Therapeutics (ANIK) Cash & Current Investments (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Cash & Current Investments for 17 consecutive years, with $38.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash & Current Investments fell 50.19% year-over-year to $38.4 million; the TTM figure through Jun 2026 stood at $38.4 million (down 50.19% YoY), while the FY2025 annual figure was $81.2 million, up 2.46% from the prior year.
- Cash & Current Investments slipped to $38.4 million in Q2 2026 per ANIK's latest filing, from $66.8 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $123.6 million in Q2 2022 and bottomed at $38.4 million in Q2 2026.
- Historically, Cash & Current Investments has averaged $93.6 million across 5 years, with a median of $95.8 million in 2023.
- Annual changes were most pronounced in 2022 — Cash & Current Investments surged 34.04% — and 2026, when it sank 50.19%.
- Anika Therapeutics' Cash & Current Investments stood at $121.0 million in 2022, then decreased by 21.38% to $95.1 million in 2023, then decreased by 16.7% to $79.2 million in 2024, then increased by 2.46% to $81.2 million in 2025, then plunged by 52.68% to $38.4 million in 2026.
- Business Quant data shows ANIK's Cash & Current Investments at $38.4 million in Q2 2026, $66.8 million in Q1 2026, and $81.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | 963.33 Mn |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 5.80 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 2.66 Bn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 389.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 164.00 Mn |
| 10 | Anika Therapeutics | 286.20 Mn | 247.78 Mn | 21.24 Mn | 38.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.41 Mn |
| Mar 31, 2026 | 66.79 Mn |
| Dec 31, 2025 | 81.17 Mn |
| Sep 30, 2025 | 80.18 Mn |
| Jun 30, 2025 | 77.12 Mn |
| Mar 31, 2025 | 75.36 Mn |
| Dec 31, 2024 | 79.22 Mn |
| Sep 30, 2024 | 90.73 Mn |
| Jun 30, 2024 | 96.60 Mn |
| Mar 31, 2024 | 100.71 Mn |
| Dec 31, 2023 | 95.10 Mn |
| Sep 30, 2023 | 105.33 Mn |
| Jun 30, 2023 | 101.81 Mn |
| Mar 31, 2023 | 110.37 Mn |
| Dec 31, 2022 | 120.95 Mn |
| Sep 30, 2022 | 121.95 Mn |
| Jun 30, 2022 | 123.56 Mn |
| Mar 31, 2022 | 119.64 Mn |
| Dec 31, 2021 | 124.23 Mn |
| Sep 30, 2021 | 90.98 Mn |